Innovations in Pharmaceutical Technology (IPT)
IPT provides a platform for cutting-edge ideas, concepts, and developments shaping the future of pharmaceutical R&D.
Install App?
Innovations in Pharmaceutical Technology (IPT)
www.iptonline.com
This is how the Install App dialog will look like once your App goes live.
The collaboration will connect PostEra’s synthesis prediction technology with Optibrium’s comprehensive platform for design, optimisation and data analysis for small molecule discovery
CAMBRIDGE, UK and BOSTON, USA, 15 March 2023 – Optibrium, a leading developer of software and AI for small molecule discovery, and PostEra, an AI-first biotechnology company with advanced machine learning (ML) technology for preclinical discovery, today announced a collaboration to integrate Optibrium’s StarDrop platform with PostEra’s Manifold software. StarDrop’s comprehensive suite of drug discovery software enables de novo compound design, optimisation, and data analysis and now, with the seamless integration of Manifold’s retrosynthesis ML capabilities, users can identify the best scalable synthetic routes.
Founded in 2019, PostEra’s cutting-edge approach has already attracted high-calibre collaborations, with institutes such as Pfizer and the National Institutes of Health teaming with PostEra on discovery projects. With this integration, PostEra joins Optibrium’s growing list of technology collaborators, including Collaborative Drug Discovery and Certara.
Manifold, a subset of PostEra’s broader medicinal chemistry platform, is a powerful retrosynthesis software that uses ML algorithms to select the best scalable routes for compound synthesis from accessible building blocks, complemented by an intuitive user interface. To streamline project timelines, starting materials which are readily available to purchase can be easily identified through dynamic connections to contract research organisations, globally. Together, StarDrop and Manifold deliver seamless data flow across design, optimisation, analysis and synthesis planning, enabling users to quickly identify and produce high quality, synthetically accessible compounds in the discovery and development of new therapeutics.
Matthew Segall, Chief Executive Officer, Optibrium, said: “We are delighted to collaborate with PostEra, whose team demonstrates an impressive focus on scientific rigour that strongly aligns with our own core values. The combination of StarDrop with Manifold’s retrosynthesis capabilities showcases Optibrium’s ongoing commitment to providing our users with the latest and most innovative technology, delivering a comprehensive AI drug discovery solution that will help scientists to further their R&D projects.”
Aaron Morris, Chief Executive Officer, PostEra, commented: “This collaboration with Optibrium is an exciting opportunity to provide drug discovery scientists with the best possible tools to overcome key challenges in preclinical workflows. By integrating our innovative software products, we hope to make a meaningful impact for patients worldwide.”
About Optibrium
Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium’s lead product, StarDrop™, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. The company’s Augmented Chemistry® products and services, including Cerella™, deliver proven artificial intelligence technologies that continuously learn from all available data to supplement researchers’ experience and skills.
Optibrium was founded in 2009 and is headquartered in Cambridge, UK, with a US subsidiary, Optibrium Inc., based in Cambridge MA. The company works closely with over 170 customers and collaborators worldwide, including leading global pharma, biotech, agrochemical and flavouring companies and not-for-profit and academic groups. For further information, visit www.optibrium.com.
About PostEra
PostEra was founded in 2019 and its technology is built on pioneering academic research done by its founding scientists. PostEra's technology addresses some of the key challenges in drug discovery R&D by integrating molecular design with chemical synthesis. PostEra advances small molecule programs via an internal pipeline and through co-discovery partnerships with biopharma, while also offering some of its synthesis technology via its Manifold platform. PostEra also launched and helps lead the world's largest open-science drug discovery effort; COVID Moonshot. For further information, visit http://www.postera.ai/.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/b2fdfcd9-5174-45b6-8d1d-9b641ad7095a.png?optimizer=image&width=360&aspect_ratio=3:4)
Austrian State Secretary to speak at FlyPharma Europe 2023
29 September 2023 -- London, UK -- FlyPharma Europe will welcome Mr Florian Tursky, the Austrian state secretary, to the conference on 10 October, where he will deliver an opening speech. He will join a host of expert industry speakers from both pharma and cargo sectors
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/e27828aa-7431-445b-8b52-d6d3b9228649.png?optimizer=image&width=360&aspect_ratio=3:4)
Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure
26 September 2023 -- Massachusetts, US -- Revvity unveils its groundbreaking Pin-point base editing platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/589e2bd7-77cb-43d6-ac4a-f0180b72bb89.png?optimizer=image&width=360&aspect_ratio=3:4)
Cellectricon Expands Neuroscience Contract Research Portfolio with New Neuroplasticity Services
26 September 2023 -- Molndal, Sweden -- Cellectricon, a services provider dedicated to advancing neuroscience drug discovery, announced the launch of a new service module for neuroplasticity research
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/3d896106-9683-4d84-b2bf-6db473ad2a53.png?optimizer=image&width=360&aspect_ratio=3:4)
Start Codon Invites Life Sciences Leaders, Founders and Investors to Innovation Showcase 2023
26 September 2023 -- Cambridge, UK -- Start Codon, a life science and healthcare venture-building fund, is pleased to invite life sciences leaders, entrepreneurs and investors from across the life science and biotech industries to attend their Innovation Showcase 2023
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/a568048c-8b7a-4d2e-9778-6f3a80fa8220.png?optimizer=image&width=360&aspect_ratio=3:4)
Evonetix Unveils New Branding to Align with its Vision for Gene-length DNA Synthesis
26 September 2023 -- Cambridge, UK -- Evonetix, the Company developing semiconductor scale technology to improve access to gene synthesis, announces the introduction of new branding to align with its vision to ‘Redefine possible’ through the development and commercialisation of its benchtop semiconductor gene synthesis platform
1
Human-Centred Design: From Inception to Integration
IPT sat down with Dr Chris Vincent at PDD, to understand more about the digital innovations that are leading design and whether technologies like Extended Reality (XR) can be beneficial to the process
2
The Importance of Temperature Control in Pharmaceutical Analysis
As technology within the analysis sphere continues to evolve, temperature control is becoming increasingly important for drug discovery and research
3
Providing Support Throughout the Patient Journey
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. How best can they be implemented?
